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Abstract
Objective. The aim was to assess how the patient-reported outcome RA impact of disease (RAID)
relates to DAS28 categories in routine care, its utility in identifying patients in DAS28 remission (RDAS)
or low disease activity (LDAS) and the burden of unmet patient-reported needs in those achieving
RDAS/LDAS.
Methods. DAS28 and RAID scores were collected from patients with established RA attending for
routine review. The relationship between RAID and DAS28 was assessed with univariate pairwise cor-
relation and mixed-effects linear regression analyses. RAID <2 was defined as a patient-acceptable
state.
Results. One hundred and ninety-eight patients were assessed, with 220 observations, using DAS28-
CRP categories: 47.5% RDAS, 14.1% LDAS, 31.8% moderate DAS (MDAS) and 6.6% high DAS
(HDAS). Both patient visual analog scale score and tender joint count exhibited a high statistical asso-
ciation with RAID using linear regression (P< 0.0001). The mean RAID score per DAS28-CRP category
was RDAS 1.84, LDAS 4.78, MDAS 5.60 and HDAS 7.68, with a statistically significant increase in
RAID per unit increase in DAS-CRP or DAS28-ESR on linear regression (P < 0.001). Of 66 patients
with RAID <2, 64 (97%) were in RDAS and 65 (98.5%) in RDAS/LDAS. Of 134 patients in RDAS/
LDAS, RAID was 2 in 69 (51.5%), with fatigue and sleep being the worst-scoring domains.
Conclusion. RAID functions well as a patient-reported outcome in routine care. Patients with RAID
<2 have a high likelihood of being in RDAS/LDAS and, if pre-screened, could avoid a clinic visit.
Analysis of RAID domains provides individualized targets for holistic care in RA management, with fa-
tigue and sleep problems dominating unmet needs in those in RDAS/LDAS.
Key words: rheumatoid arthritis, disease activity score, RAID, patient-reported outcomes
Introduction
Treat-to-target principles are widely recognized as the
best strategy to achieve optimal disease outcomes in
RA [1]. Two target outcomes are proposed within both
ACR and EULAR guidelines [2, 3], and these have been
endorsed by national bodies, such as the National
Institute for Health and Care Excellence [4]. These tar-
gets, either remission or low disease activity, are based
on the DAS28 composite score, which includes ob-
server-, laboratory- and patient-reported assessments of
disease activity.
Inflammation in RA has been linked clearly to joint
damage and adverse cardiovascular outcomes, and in
broad terms, new therapies and treatment strategies
have been successful in suppressing both inflammation
and its consequences [5, 6]. However, it has become in-
creasingly clear that advances in RA management have
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had less impact on some patient-reported outcomes,
such as fatigue, pain, depression, work performance
and health-related quality of life [7–9].
Given the discordance in RA outcomes assessed by
composite measures based on inflammation vs patient-
reported outcomes, it is evident that to be truly holistic
the management of RA in a treat-to-target context
should include assessment of both aspects (inflamma-
tion and patient-reported outcome) in routine practice.
DAS28 and SDAI provide assessments based on ob-
server, patient and laboratory assessments. A variety of
composite patient-reported outcomes is available to
complement these, such as RA impact of disease
(RAID), five item RA disease activity index (RADAI-5)
and the Routine Assessment of Patient Index Data 3
(RAPID3). The RAID score is a patient-derived differen-
tially weighted seven-item tool assessing pain, functional
disability, fatigue, sleep, coping, physical and emotional
well-being. It has been validated, is reliable, sensitive to
change and EULAR adopted [10, 11]. It is well corre-
lated with RADAI, patient global measures, SF36 physi-
cal and mental subscales, Euro Quality of Life 5
dimension index (EQ5D) and the DAS28 score [10, 12,
13]. On an individual patient level, a score <2 is deemed
a patient-acceptable state [14, 15], and both absolute
and relative minimally clinical important improvements
are also defined [14].
In an increasingly over-populated and time-
constrained health-care service, a particular attraction of
RAID is its simplicity, with applicability to patient com-
pletion at home and submission electronically, poten-
tially avoiding the need for a face-to-face consultation.
We have therefore assessed the utility of RAID in routine
care as a tool to identify patients in DAS28 remission
(RDAS) or low disease activity (LDAS) and to reveal the
burden of unmet patient needs in those achieving
RDAS/LDAS.
Methods
Patients attending for routine RA review at St George’s
University Hospitals NHS Foundation Trust were
assessed by a rheumatologist, nurse practitioner or phy-
sician assistant. Data collected at each clinic visit in-
cluded the DAS28 score, acute phase reactants and the
RAID questionnaire. All data were collected as standard
routine care practice. Patients gave verbal consent to
pooled retrospective data analysis.
The RAID score was calculated using the online EULAR
toolkit [11]. Each of the seven individual domains of the
RAID is scored on a 10-item numerical rating scale, with
zero being a good or low activity score and 10 a high or
severe activity score. In the absence of guidance, we ar-
bitrarily classified the numerical rating scale results into
one of three equivalent-sized ranges (mild: 0–2; moder-
ate: 3–6; severe: 7–10) to give an overall idea of which
domains scored particularly poorly or well.
The DAS28-ESR thresholds for remission (<2.6), low
(2.6–3.2), moderate (3.3–5.1) and high (>5.1) disease ac-
tivity were used, whereas for DAS28-CRP adjusted
thresholds were adopted, remission (<2.4), low (2.4–
2.9), moderate (2.91–4.6) and high (>4.6) disease activ-
ity, respectively [16].
Seropositive status was defined as testing positive for
either RF or ACPA, or both. Only those who tested neg-
ative for both RF and ACPA were defined as
seronegative.
The relationship between RAID scores with both
DAS28-CRP and DAS28-ESR and their subcomponents
was initially explored descriptively by comparing mean
scores and univariate pairwise correlation analysis. The
swollen joint count and tender joint count scores were
square-root transformed, whereas the ESR and CRP
were logarithmically transformed to match their form
used in the DAS28 formulation. The relationship be-
tween each subcomponent of the DAS28 and the RAID
score was explored using mixed-effects linear regres-
sion. Mixed-effects regression allows multiple observa-
tions per patient to be modelled, accounting for the
likely correlation attributable to non-independence within
these observations. The model included all subcompo-
nents of the DAS28 and controlled for important con-
founders, including age, sex and seropositive status.
The analyses were conducted separately for the DAS28-
CRP and DAS28-ESR. All analyses were conducted us-
ing Stata v.15.
Results
One hundred and ninety-eight patients with established
RA were assessed, contributing 220 observations. The
sample was 80.8% female, mean age 59.0 years, 72.2%
RF positive and 77.8% ACPA positive. Our of all the
patients, 84.8% tested positive for either RF or ACPA
(or both) and were defined as seropositive RA. Patients
were on a range of therapies, including conventional
synthetic DMARDs and biologic DMARDs, managed
according to standard care.
DAS28-CRP was available for all 198 patients. The
number in RDAS at first observation was 94 (47.5%),
Key messages
. RAID functions well in routine care and is closely associated with subjective components of DAS28.
. Patients with a RAID score <2 are highly likely to be in RDAS or LDAS.
. Fatigue and sleep are the worst-scoring domains in R/LDAS patients with a RAID >2.
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LDAS 28 (14.1%), MDAS 63 (31.8%) and HDAS 13
(6.6%). The distribution per DAS28-ESR category was
similar, with RDAS 46.7%, LDAS 16.8%, MDAS 29.4%
and HDAS 7.1%.
The RAID scores were recorded 218 times from 196
patients, with a mean of 3.87 (S.D. 2.55), range 0–9.64.
Patients reported no difficulties in understanding or
completing the questions, taking <5 min. Only two ques-
tionnaires (1%) had missing data. The requirement to
complete the RAID questionnaire during the consultation
caused no delays to the normal conduct and running of
the clinics.
Fig. 1 shows the relationship between RAID scores
and DAS28-CRP, Spearman correlation 0.78. RAID
scores were also correlated strongly with DAS28-ESR
(r¼0.75) and patient global visual analog scale
(r¼0.83), but less well with the square-root of tender
joint count (r¼0.55), square-root of swollen joint count
(r¼0.39), log ESR (r¼ 0.38) and log CRP (r¼ 0.30).
Using multiple mixed-effects linear regression, both
the patient global visual analog scale and the square-
root of tender joint count exhibited a highly statistically
significant association with RAID scores (P <0.01),
whereby high tender joint count and patient global as-
sessment were associated with increased scores on the
RAID. Standardized coefficients indicate that the patient
global visual analog scale had the largest association at
0.65, followed by tender joint count at 0.23. Additionally,
the log CRP indicated statistical significance at
P ¼0.048, although the level and comparative effect
were small relative to the tender joint count and patient
global assessment, with a standardized coefficient of
0.08. The results are provided in Supplementary Table
S1, available at Rheumatology Advances in Practice
online.
The mean RAID score per DAS28-CRP disease activity
category was RDAS 1.84 (S.D. 1.55), LDAS 4.78 (S.D. 1.73),
MDAS 5.60 (S.D. 1.63) and HDAS 7.68 (S.D. 1.29) (see
Supplementary Fig. S1, available at Rheumatology
Advances in Practice online). When modelled using
mixed-effects linear regression, whilst controlling for age,
sex and seropositivity, there was a statistically significant
increase in RAID scores for each one unit increase in
DAS28-CRP score (b ¼ 1.76; 95% CI: 1.59, 1.94, P
< 0.001). Likewise, when DAS28-ESR was modelled in a
mixed-effects linear regression, controlling for age, sex
and seropositivity, there was a statistically significant in-
crease in RAID scores for each one unit increase in
DAS28-ESR (b ¼ 1.43; 95% CI: 1.28, 1.58, P < 0.001),
with mean RAID score per DAS28-ESR disease activity
category, RDAS 2.14 (S.D. 1.93), LDAS 4.16 (S.D. 1.96),
MDAS 5.52 (S.D. 1.62) and HDAS 7.52 (S.D. 1.59).
Of 66 patients with RAID <2 (patient-acceptable
state), DAS28-CRP was <2.4 in 64 (97%) and 2.9 in
65 (98.5%); likewise, DAS28-ESR was < 2.6 in 61
(92.4%) and 3.2 in 65 (98.5%).
Of 105 patients with DAS28-CRP <2.4 (remission),
RAID was 2 in 41 (39%), and of 134 patients with
DAS28-CRP 2.9 (remission and low disease activity)
RAID was 2 in 69 (51.5%). Fig. 2 shows the proportion
FIG 1 The relationship between DAS28-CRP and RA impact of disease scores
RAID: RA impact of disease.
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of patients with DAS28-CRP 2.9 and RAID 2 scoring
mild (0–2), moderate (3–6) and severe (7–10) for each
domain of the RAID questionnaire. The domains with the
largest proportion of these patients scoring in the severe
range were fatigue 35.6%, sleep 33.3% and emotional
well-being 28.9%. None of the seven domains scored
uniformly well, the best being functional disability and
coping, where 35.6 and 33.3% of patients, respectively,
scored 0–2 on these domains.
Discussion
This is the first report of the utility of the RAID patient-
reported outcome measure in a routine care setting in
UK practice. The score is well correlated with the total
DAS28-CRP or DAS28-ESR score and with patient
global assessment and tender joint count, but not with
swollen joint count, CRP or ESR, as found by others
[10, 12] and in keeping with this being a patient-derived
outcome, rather than a measure of inflammation.
Significant differences in RAID scores between patients
in RDAS, LDAS, MDAS and HDAS categories, whether
using DAS28-CRP or DAS28-ESR, confirm previous
reports that there are significant differences in patient-
reported outcomes between these categories, including
remission and low disease activity in early RA [17, 18].
Our findings in a mixed population of patients with
established RA under routine review add support to re-
mission being a preferable goal compared with low dis-
ease activity in treat-to-target terms.
A very practical utility of RAID in routine care is appar-
ent from the fact that virtually all patients with a RAID
<2, defined as a patient-acceptable state [14, 15], were
also either in RDAS or in LDAS. As such, if the RAID
score is <2 it may be assumed confidently that the pa-
tient has also achieved a DAS28 treat-to-target goal. If
developed as a tool for use at home, for example via a
telephone app, the RAID could function as a triage tool,
potentially avoiding the need for a face-to-face disease
activity assessment in the clinic. This would be an inno-
vative advance in an over-populated and resource-
limited health-care system, where priority is better given
to those RA patients with unsuppressed disease activity,
requiring active changes in treatment.
In contrast, where the RAID is >2 the range of DAS28
scores is very wide (see Fig. 1), and inferences cannot
be made. Of particular note is the fact that 51.5% of all
patients who have achieved the DAS28 CRP treat-to-
target LDAS or RDAS outcome (2.9) have a RAID
score 2, in an unacceptable patient range. This repre-
sents a high proportion of LDAS and RDAS patients
with unmet needs and indicates that there is much
scope for investigation and improved intervention strate-
gies for these patients who have achieved seemingly
good DAS28 outcomes. The RAID has additional utility
in this regard, because scrutiny of the seven domains
identifies those areas with particularly poor scores, en-
abling focused interventions, such as cognitive behav-
ioural techniques. We found fatigue and sleep to be the
most frequent high-scoring domains in patients in
DAS28-CRP RDAS/LDAS but with a RAID 2. Fatigue is
widely described to be a persisting long-term symptom
in RA patients, including those in remission defined by
DAS [7, 9, 19, 20], and our data are consistent with this.
However, many patients scored poorly on all of the seven
domains, indicating the need for a widespread package
of care for truly holistic management. The high proportion
FIG. 2 Patients with DAS28-CRP  2.9 (LDAS and RDAS) and RAID score  2 (n¼ 69)
Distribution (percentage) scoring each RAID domain: mild (0–2), moderate (3–6) or severe (7–10). LDAS: low DAS;
RAID: RA impact of disease; RDAS: remission.
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of patients with a RAID score in the unacceptable range
(2), yet in LDAS or RDAS, argues for a dual treat-to-
target strategy incorporating both an inflammation-
derived target and a patient-reported outcome target to
be holistic. This is in keeping with the conclusions of
Ferreira et al. [21], who advocate a three-component
composite score (swollen joint count, tender joint count
and CRP) as the target for immunosuppressive therapy
and a separate disease impact target based on an ex-
panded analysis of the patient global score, such as
RAID. Our findings confirm that the RAID does function
well as a treat-to-target patient-reported outcome, aiming
for a score <2. The strength of our findings is that they
demonstrate the utility of RAID in a real-world routine care
setting. Nonetheless, the data are preliminary, because
they are from only one centre, and they should be repli-
cated in other settings and in larger numbers.
In summary, we have found the RAID questionnaire to
be simple and easy to incorporate into the routine care
setting for patients with RA. The finding that >97% of all
patients with a score in the patient-acceptable range <2
are also in the DAS28-CRP categories of LDAS or RDAS
provides potential time-saving utility by avoiding face-to-
face disease activity assessments for these patients.
Conversely, RAID reveals a high burden of unmet needs
in patients in RDAS/LDAS, with >50% scoring 2.
Scrutiny of the seven domains assessed provides individ-
ualized opportunities for improved RA management, es-
pecially for fatigue and sleep problems. For truly holistic
care, there should be two treat-to-target goals, one based
on an inflammation-derived measure and one on a
patient-reported outcome. The RAID performs well as a
patient-reported outcome in routine care.
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